Head of the Stem Cell R&D Transformational Research Unit at Novo Nordisk, responsible for the entire R&D value chain, from research, clinical development, CMC and manufacturing. Member of the Novo Nordisk R&D Bioethics Council. Previous areas of responsibility in global research at Novo Nordisk includes therapeutic area head for diabetes, stem cells obesity and NASH.
2001-2002: Executive Chief Scientific Officer Inoxell Inc. Denmark, focusing on finding novel drug targets in cancer and inflamation.
1998-2001: Head of Islet Discovery Research, Novo Nordisk Denmark: Working with diabetes and inflammation. 1995-1998: Senior scientist/project manager at ZymoGenetics inc. Seattle USA: Working on diabetes intervention/prevention and inflamation.
1989- 1995: Ph.D student and later Staff scientist Hagedorn Research Institute, Gentofte Denmark: Research focus on inflamation, islet biology and type 1 diabetes.
From 2010 professor in biomedicine at the medical faculty in Copenhagen University. In 2006 awarded the doctor of medical science (DMSc) degree from the medical faculty Copenhagen University Denmark. Member of the board of directors of JDRF Denmark (chairman) Besides numerous presentations at international conferences, published approx. 60+ papers in peered reviewed journals mainly on topics of diabetes prediction, prevention and intervention but also on beta cell biology, physiology and immunology.